Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY GroupLJUIF 87 Return-on-Tangible-Asset is 3.28% as of Dec. 2025, which is 71% below its 10-year median of 11.16. GuruFocus rates LJUIF with a GF Score™ of 87/100 and a GF Value™ of $0.51. The stock has 8 warning signs investors should review. Among 1,008 Drug Manufacturers companies, SSY Group ranks better than 54.96% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. SSY Group's annualizedNet Income for the quarter that ended in Dec. 2025 was $48.1 Mil. SSY Group's average total tangible assets for the quarter that ended in Dec. 2025 was $1,467.4 Mil. Therefore, SSY Group's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 3.28%.
The historical rank and industry rank for SSY Group's Return-on-Tangible-Asset or its related term are showing as below:
LJUIF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 4.12 Med: 11.16 Max: 16.76
Current: 4.12
During the past 13 years, SSY Group's highest Return-on-Tangible-Asset was 16.76%. The lowest was 4.12%. And the median was 11.16%.
LJUIF's Return-on-Tangible-Asset is ranked better than 54.96% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.05
vs LJUIF: 4.12
SSY Group (OTCPK:LJUIF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
SSY Group Return-on-Tangible-Asset Related Terms
SSY Group Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for SSY Group's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where SSY Group's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 3.28% mean?
SSY Group (LJUIF) has a Return-on-Tangible-Asset of 3.28% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on SSY Group and its competitors. This is 71% below median its historical median of 11.16. Over the past decade, SSY Group's Return-on-Tangible-Asset has ranged from 4.12 to 16.76. According to the industry distribution chart, SSY Group ranks #454 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 45%.
Is SSY Group's Return-on-Tangible-Asset too high?
SSY Group's current Return-on-Tangible-Asset of 3.28% is 71% below median its 10-year median of 11.16. Over the past 10 years, this metric has ranged from a low of 4.12 to a high of 16.76. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.05. SSY Group's value of 3.28% is 7.5% above this industry median. Based on the distribution chart, SSY Group ranks #454 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, SSY Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does SSY Group's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #454 out of 1008 companies for Return-on-Tangible-Asset. This puts SSY Group in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.05. SSY Group's value of 3.28% is 7.5% above this benchmark. Historically, SSY Group's own Return-on-Tangible-Asset has ranged from 4.12 to 16.76 over the past decade. While the company's 10-year median is 11.16 vs. the industry median of 3.05, SSY Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.05, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current Return-on-Tangible-Asset of 3.28% is 7.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current Return-on-Tangible-Asset is 3.28%, which is 71% below median its own 10-year median of 11.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
SSY Group (LJUIF) has a current Return-on-Tangible-Asset of 3.28%. The stock's GF Value™ is $0.51, compared to a current price of $0.40 — trading 21.1% below its estimated fair value. The current Return-on-Tangible-Asset is 3.28%, which is 71% below median its 10-year median of 11.16 and 7.5% above the Drug Manufacturers industry median of 3.05. SSY Group's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For SSY Group (LJUIF), the current Return-on-Tangible-Asset is 3.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (LJUIF) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of $0.40 is trading 21.1% below its estimated GF Value™ of $0.51.
Key valuation signals for LJUIF:
Return-on-Tangible-Asset: 3.28% (71% below median its 10-year median of 11.16)
GF Value™: $0.51 vs. price of $0.40 (21.1% below fair value)
Industry Position: 7.5% above the Drug Manufacturers median (#454 of 1008)
No single metric tells the full story. See the LJUIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
87GF Score
Get the complete analysis for LJUIF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LJUIF has been successfully added to your 
